First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)

Cancer Invest. 2017 Sep 14;35(8):541-546. doi: 10.1080/07357907.2017.1344698. Epub 2017 Aug 1.

Abstract

Background: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC.

Methods: Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m2 IV, and carboplatin AUC = 6 IV every 21 days. After 6 cycles, maintenance therapy with panitumumab and pemetrexed was administered every 21 days until progressive disease or unacceptable toxicity.

Results: 29 of 66 patients (44%) had objective responses. The median TTP was 6 months; median overall survival (OS) was 17 months. Panitumumab increased treatment-related toxicity, notably skin rash.

Conclusions: The addition of panitumumab increased toxicity, and had no discernible impact on efficacy.

Keywords: EGFR inhibitor; KRAS wild-type; NSCLC; Panitumumab.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage*
  • Carboplatin / adverse effects
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Drug Administration Schedule
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Panitumumab
  • Pemetrexed / administration & dosage*
  • Pemetrexed / adverse effects
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • KRAS protein, human
  • Pemetrexed
  • Panitumumab
  • Carboplatin
  • Proto-Oncogene Proteins p21(ras)